Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to$291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from$1.44 a year ago, in line with the Wall Street Estimate.Also Read: Wegovy Maker Novo Nordisk To Buy Novavax’s Czech Republic Manufacturing Facility For $200 Million“In 2024, we unveiled our new corporate ...